92 related items for PubMed ID: 9283216
1. [A prospective controlled study of sairei-to in childhood IgA nephropathy with focal/minimal mesangial proliferation. Japanese Pediatric IgA Nephropathy Treatment Study Group].
Yoshikawa N, Ito H, Sakai T, Takekoshi Y, Honda M, Awazu M, Ito K, Iitaka K, Koitabashi Y, Yamaoka K, Nakagawa K, Nakamura H, Matsuyama S, Seino Y, Takeda N, Hattori S, Ninomiya M.
Nihon Jinzo Gakkai Shi; 1997 Jul; 39(5):503-6. PubMed ID: 9283216
[Abstract] [Full Text] [Related]
2. Steroid treatment for severe childhood IgA nephropathy: a randomized, controlled trial.
Yoshikawa N, Honda M, Iijima K, Awazu M, Hattori S, Nakanishi K, Ito H, Japanese Pediatric IgA Nephropathy Treatment Study Group.
Clin J Am Soc Nephrol; 2006 May; 1(3):511-7. PubMed ID: 17699253
[Abstract] [Full Text] [Related]
3. [Expression and clinical implication of platelet-derived growth factor-D and platelet-derived growth factor-beta in childhood IgA nephropathy].
Rong ZH, Wang C, Hao J, Duan HJ.
Zhongguo Wei Zhong Bing Ji Jiu Yi Xue; 2008 May; 20(5):275-8. PubMed ID: 18471357
[Abstract] [Full Text] [Related]
4. [Standard versus long-term prednisolone with sairei-to for initial therapy in childhood steroid-responsive nephrotic syndrome: a prospective controlled study].
Yoshikawa N, Ito H, Takekoshi Y, Honda M, Awazu M, Iijima K, Nakamura H, Seino Y, Takeda N, Hattori S, Matsuda I.
Nihon Jinzo Gakkai Shi; 1998 Nov; 40(8):587-90. PubMed ID: 9893457
[Abstract] [Full Text] [Related]
5. The treatment of mesangial IgA nephropathy with cyclophosphamide, dipyridamole and warfarin: a two-year prospective trial.
Walker RG, Yu SH, Owen JE, Kincaid-Smith P.
Clin Nephrol; 1990 Sep; 34(3):103-7. PubMed ID: 2225560
[Abstract] [Full Text] [Related]
6. Combined therapy in children and adolescents with IgA nephropathy.
Murakami K, Yoshioka K, Akano N, Takemura T, Okada M, Aya N, Hino S, Miyazato H, Yagi K, Maki S.
Nihon Jinzo Gakkai Shi; 1994 Jan; 36(1):38-43. PubMed ID: 8107307
[Abstract] [Full Text] [Related]
7. ANCA-associated crescentic glomerulonephritis with mesangial IgA deposits.
Haas M, Jafri J, Bartosh SM, Karp SL, Adler SG, Meehan SM.
Am J Kidney Dis; 2000 Oct; 36(4):709-18. PubMed ID: 11007672
[Abstract] [Full Text] [Related]
8. Focal segmental glomerulosclerosis in mild IgA nephropathy: a clinical-pathologic study.
Weber CL, Rose CL, Magil AB.
Nephrol Dial Transplant; 2009 Feb; 24(2):483-8. PubMed ID: 18786972
[Abstract] [Full Text] [Related]
9. [Primary nephrotic syndrome. Follow-up of 202 pediatric patients].
Caletti MG, Gallo G, Zumino D, Díaz MA, Vitacco M.
Bol Med Hosp Infant Mex; 1981 Feb; 38(3):457-72. PubMed ID: 7271977
[Abstract] [Full Text] [Related]
10. Treatment of IgA nephropathy with eicosapentanoic acid (EPA): a two-year prospective trial.
Bennett WM, Walker RG, Kincaid-Smith P.
Clin Nephrol; 1989 Mar; 31(3):128-31. PubMed ID: 2539929
[Abstract] [Full Text] [Related]
11. The effectiveness of steroid therapy for patients with advanced IgA nephropathy and impaired renal function.
Moriyama T, Honda K, Nitta K, Yumura W, Nihei H.
Clin Exp Nephrol; 2004 Sep; 8(3):237-42. PubMed ID: 15480901
[Abstract] [Full Text] [Related]
12. [Immunosuppressive therapy of glomerulonephritis--controlled studies].
Ferrari P, Frey FJ.
Ther Umsch; 1993 Feb; 50(2):119-29. PubMed ID: 8456416
[Abstract] [Full Text] [Related]
13. Clinical trial to evaluate omega-3 fatty acids and alternate day prednisone in patients with IgA nephropathy: report from the Southwest Pediatric Nephrology Study Group.
Hogg RJ, Lee J, Nardelli N, Julian BA, Cattran D, Waldo B, Wyatt R, Jennette JC, Sibley R, Hyland K, Fitzgibbons L, Hirschman G, Donadio JV, Holub BJ, Southwest Pediatric Nephrology Study Group.
Clin J Am Soc Nephrol; 2006 May; 1(3):467-74. PubMed ID: 17699247
[Abstract] [Full Text] [Related]
14. Berger's disease in children. Natural history and outcome.
Lévy M, Gonzalez-Burchard G, Broyer M, Dommergues JP, Foulard M, Sorez JP, Habib R.
Medicine (Baltimore); 1985 May; 64(3):157-80. PubMed ID: 3887094
[Abstract] [Full Text] [Related]
15. Blood pressure reduction associated with preservation of renal function in hypertensive patients with IgA nephropathy: a 3-year follow-up.
Kanno Y, Okada H, Saruta T, Suzuki H.
Clin Nephrol; 2000 Nov; 54(5):360-5. PubMed ID: 11105796
[Abstract] [Full Text] [Related]
16. T cell subsets in glomerulonephritis.
Lin CY, Yang YM, Fu YK.
Int J Pediatr Nephrol; 1986 Nov; 7(2):63-8. PubMed ID: 3487514
[Abstract] [Full Text] [Related]
17. A controlled trial of combined therapy for newly diagnosed severe childhood IgA nephropathy. The Japanese Pediatric IgA Nephropathy Treatment Study Group.
Yoshikawa N, Ito H, Sakai T, Takekoshi Y, Honda M, Awazu M, Ito K, Iitaka K, Koitabashi Y, Yamaoka K, Nakagawa K, Nakamura H, Matsuyama S, Seino Y, Takeda N, Hattori S, Ninomiya M.
J Am Soc Nephrol; 1999 Jan; 10(1):101-9. PubMed ID: 9890315
[Abstract] [Full Text] [Related]
18. Macroscopic hematuria in childhood IgA nephropathy.
Yoshikawa N, Ito H, Iijima K, Nakahara C, Maehara K, Hasegawa O, Okada S, Matsuo T.
Clin Nephrol; 1987 Nov; 28(5):217-21. PubMed ID: 3427831
[Abstract] [Full Text] [Related]
19. Effect of corticosteroid therapy on the progression of IgA nephropathy with moderate proteinuria.
Uzu T, Harada T, Ko M, Yamato M, Takahara K, Yamauchi A.
Clin Exp Nephrol; 2003 Sep; 7(3):210-4. PubMed ID: 14586717
[Abstract] [Full Text] [Related]
20. Randomized controlled clinical trial of corticosteroids plus ACE-inhibitors with long-term follow-up in proteinuric IgA nephropathy.
Manno C, Torres DD, Rossini M, Pesce F, Schena FP.
Nephrol Dial Transplant; 2009 Dec; 24(12):3694-701. PubMed ID: 19628647
[Abstract] [Full Text] [Related]
Page: [Next] [New Search]
